Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Emergent BioSolutions Inc. Common Stock (NY:EBS)

6.400 -0.100 (-1.54%)
Official Closing Price Updated: 7:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Emergent BioSolutions Inc. Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
15 16 Next >
FDA Approves First OTC Naloxone Nasal Spray For Opioid Overdose
Via Benzinga
FDA Approves Over The Counter Sale Of Opioid Reversal Drug Narcan
Narcan, the prescription nasal spray that reverses opioid overdoses can now be sold over the counter (OTC), said the FDA on Wednesday, reported the NY Times, thereby authorizing a move that has... 
Via Benzinga
U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment
From Emergent BioSolutions
Via GlobeNewswire
Why Emergent Biosolutions Stock Is Surging Today
Emergent Biosolutions Inc (NYSE: EBS) shares are trading higher Wednesday following reports the U.S. Food and Drug Administration approved the company's Naloxone nasal spray for over-the-counter use. 
Via Benzinga
Why Emergent BioSolutions Stock Is Sinking Today
Investors reacted negatively to an analyst's downgrade of the healthcare stock. 
Via The Motley Fool
Earnings Outlook For Emergent BioSolutions
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Shift Technologies Shares Are Trading Lower By 15%; Here Are 20 Stocks Moving Premarket
Gainers LogicMark, Inc. (NASDAQ: LGMK) shares rose 36.7% to $0.1914 in pre-market trading after the company reported strong revenue and margin growth for the year ended 2022. 
Via Benzinga
Cal-Maine Foods, Lululemon Athletica And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
First Republic Bank, Blend Labs, Purple Innovation And Other Big Stocks Moving Lower On Friday
U.S. stocks traded lower, with the Dow Jones dropping more than 400 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why Baidu Shares Are Trading Higher By More Than 6%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Enzo Biochem, Inc. (NYSE: ENZ) gained 86.5% to $2.22 after the company announced it will sell its clinical laboratory to Labcorp. 
Via Benzinga
Why Cassava Sciences Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2023
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time for another breakdown of the biggest pre-market stock movers traders will want to know about on Thursday morning! 
Via InvestorPlace
Jim Cramer Says He's Known Novavax Is 'Worthless' For 'Very Long Time,' Trashes Company For Being Too 'Promotional'
Novavax Inc (NASDAQ: NVAX) shares are crashing Wednesday after the company warned that substantial doubt exists regarding its ability to continue.  Jim Cramer isn't surprised. 
Via Benzinga
Why Emergent BioSolutions Stock Tumbled by Almost 12% Today
It's not a good day for investors when their company reports a shocking plunge into the red. 
Via The Motley Fool
Emergent BioSolutions (EBS) Q4 2022 Earnings Call Transcript
EBS earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
From Emergent BioSolutions
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Earnings Scheduled For February 27, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million. 
Via Benzinga
Why Axcella Health Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
Gainers Axcella Health Inc. (NASDAQ: AXLA) shares rose 54.1% to $0.9290 in pre-market trading after the company announced FDA clearance of its IND application to initiate a phase 2b/3 trial in the U.S.... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day with an overview of the biggest pre-market stock movers worth keeping an eye on Thursday morning! 
Via InvestorPlace
Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use
From Emergent BioSolutions
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Monkeypox Vaccine Maker Bavarian Nordic Bets $380M On Emergent Bio's Travel Vaccines
Via Benzinga
Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023
From Emergent BioSolutions
Via GlobeNewswire
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Johnson & Johnson Cuts Production, Ends Contracts For Not So Successful COVID-19 Shot
Johnson & Johnson (NYSE: JNJ) has significantly scaled back its efforts of manufacturing its COVID-19 vaccine after facing a fall in demand. 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.